| Company Name: |
Amatek Scientific Co. Ltd.
|
| Tel: |
0512-56316828 |
| Email: |
info@amateksci.com |
| Products Intro: |
Product Name:BnO-PEG4-CH2CH2COOH/4,7,10,13,16-Pentaoxaheptadecanoic acid, 17-phenyl-
CAS:2514948-41-3
Purity:97% HPLC Package:5g;25g;100g;1kg
|
| Company Name: |
Xi'an Confluore Biological Technology Co., Ltd.
|
| Tel: |
+86-156-80926068 +86-15680926068 |
| Email: |
1924344760@qq.com |
| Products Intro: |
Product Name:Benzyl-PEG5-acid
CAS:2514948-41-3
Purity:98% HPLC Package:10MG;25MG;50MG;100MG;1G;5G Remarks:For customers outside China,please use the website:www.confluore.com
|
| Company Name: |
Zhengzhou Convergence Chemical Co. LTD
|
| Tel: |
0371-53736046 13393710386 |
| Email: |
2853979814@qq.com |
| Products Intro: |
Product Name:1-Phenyl-2,5,8,11,14-pentaoxaheptadecan-17-oic acid
CAS:2514948-41-3
Purity:97% Package:1g;5g;25g
|
4,7,10,13,16-Pentaoxaheptadecanoic acid, 17-phenyl- manufacturers
- Benzyl-PEG5-acid
-
- $0.00 / 5g
-
2024-03-25
- CAS:2514948-41-3
- Min. Order: 5g
- Purity: >98.00%
- Supply Ability: 5g
|
| | 4,7,10,13,16-Pentaoxaheptadecanoic acid, 17-phenyl- Basic information |
| Product Name: | 4,7,10,13,16-Pentaoxaheptadecanoic acid, 17-phenyl- | | Synonyms: | 4,7,10,13,16-Pentaoxaheptadecanoic acid, 17-phenyl-;1-Phenyl-2,5,8,11,14-pentaoxaheptadecan-17-oic acid;BnO-(CH2CH2O)4-CH2CH2COOH;BnO-PEG4-CH2CH2COOH/4,7,10,13,16-Pentaoxaheptadecanoic acid, 17-phenyl- | | CAS: | 2514948-41-3 | | MF: | C18H28O7 | | MW: | 356.41 | | EINECS: | | | Product Categories: | | | Mol File: | 2514948-41-3.mol |  |
| | 4,7,10,13,16-Pentaoxaheptadecanoic acid, 17-phenyl- Chemical Properties |
| Boiling point | 490.8±45.0 °C(Predicted) | | density | 1.135±0.06 g/cm3(Predicted) | | pka | 4.28±0.10(Predicted) |
| | 4,7,10,13,16-Pentaoxaheptadecanoic acid, 17-phenyl- Usage And Synthesis |
| Biological Activity | Benzyl-PEG5-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1]. | | References | [1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562 |
| | 4,7,10,13,16-Pentaoxaheptadecanoic acid, 17-phenyl- Preparation Products And Raw materials |
|